Andreas Engert – författare

This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progressin the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

The closed corporation is the most important economic form of business organization worldwide; however, it is often neglected in international academic legal discussions. The new special edition of the ZGR (Zeitschrift für Unternehmens- und Gesellschaftsrecht) attempts to fill this gap in research. The examination systematically addresses the typical areas of conflict with regard to a closed corporation. In do so, legally-based comparative experience and findings from business economics are applied, while the European private company is consistently taken into account.